IMPACT Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours
- Coordinator
- Impact Biotech Ltd, Israel
- Runs
- 1 December 2024 to 30 November 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101188848
What the project is doing
In the project's own words, from its summary on CORDIS.
UTUC is a non-systemically treatable cancer that forms in the renal pelvis or ureter, frequently recurring due to ineffective systemic chemotherapy. With 5-10% of urothelial cancers being UTUC, current surgical treatment solutions pose significant hardships on patients and decrease their quality of life. Our proprietary solution, Padeliporfin-VTP therapy, offers a minimally invasive and effective alternative to surgery.
This therapy delivers an inactive photosensitizer drug that is precisely activated in the tumour micro-environment by non-thermal laser light, immediately impeding the tumour's blood supply, leading to cell death with minimal effect on healthy tissues. This treatment not only effectively eliminates tumours, but also preserves organ functionality for potential future treatments. This project is led by a team of accomplished professionals in the pharmaceutical and biopharma industry, which solidifies our capability in innovating best-in-class therapeutic solutions.
Utilising this funding, we aim to achieve regulatory approval (TRL9), scale production, and achieve market penetration in a market projected to reach €4.39B by 2032.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Impact Biotech Ltd | Ness Tziona | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI